2019 R&D portfolio in review: Filaria – river blindness

With first-in-human studies for emodepside in healthy volunteers successfully completed, preparations are underway to run a Phase II clinical trial at two sites in Ghana. In the Democratic Republic of Congo, training and trial site renovations are advancing ahead of a Phase II proof-of-concept study for TylAMac, which was shown to be safe and well-tolerated in Phase I studies. And new efforts to identify novel treatments against ‘nematode’ worms have kicked off following the launch of a new multidisciplinary consortium: the Helminth Elimination Platform (HELP).

Neue öffentlich-private Partnerschaft zur Entwicklung von Medikamenten gegen parasitäre Wurminfektionen lanciert

Genf – 28. November 2019
Ein neues Konsortium bestehend aus Forschungsinstituten, Universitäten, gemeinnützigen Organisationen und Pharmaunternehmen hat sich zusammengeschlossen, um neue Medikamente gegen Infektionen verursacht durch parasitäre Würmer (Helminthen) zu entwickeln. Zu diesen Krankheiten zählen die Flussblindheit und lymphatische Filariose sowie Infektionen mit Haken- und Peitschenwürmern. Fast eine Milliarde Menschen weltweit sind betroffen.

Public-private partnership launched to develop new drugs for roundworm infections

Geneva – 28 November 2019
“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme
A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.

DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.

Study shows that African eye worm threatens elimination of river blindness

Washington DC, USA – 20 November 2019
Over four million people will be infected with river blindness in 2025 in areas where African eye worm is present, according to new modelling
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm’, according to a study published in Clinical Infectious Diseases.

ASTMH 2019

68th Annual Meeting

20-24 November 2019
National Harbor, USA

  • Symposium on tools to accelerate elimination of onchocerciasis
  • Presentations on onchocerciasis, lymphatic filariasis, leishmaniasis, clinical trials, and Chagas disease.